Antibody-based therapy of acute myeloid leukemia with gemtuzumab ozogamicin

Frontiers in Bioscience

Volumn 18, Issue 4, 2013, Pages 1311-1334

  Cowan, Andrew J ^a   Laszlo, George S ^b   Estey, Elihu H ^b,c   Walter, Roland B ^a,b,c  

^a UNIVERSITY OF WASHINGTON   (United States)

^b Fred Hutchinson Cancer Research Center   (United States)

^c UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

AML; Antibody; Calicheamicin; CD33; Gemtuzumab ozogamicin; Immunoconjugate; Review

Indexed keywords

EID: 84880531303     PISSN: 27686701     EISSN: 27686698     Source Type: Journal    
DOI: 10.2741/4181     Document Type: Article

References (185)

1. R. Siegel, D. Naishadham and A. Jemal: Cancer statistics, 2012. CA Cancer J Clin, 62(1), 10-29 (2012).
2. B. Löwenberg, J. R. Downing and A. Burnett: Acute myeloid leukemia. N Engl J Med, 341(14), 1051-1062 (1999). (Pubitemid 29451802)
3. M. S. Tallman, D. G. Gilliland and J. M. Rowe: Drug therapy for acute myeloid leukemia. Blood, 106(4), 1154- 1163 (2005). (Pubitemid 41130866)
4. E. Estey and H. Döhner: Acute myeloid leukaemia. Lancet, 368(9550), 1894-1907 (2006). (Pubitemid 44794525)
5. H. Döhner, E. H. Estey, S. Amadori, F. R. Appelbaum, T. Büchner, A. K. Burnett, H. Dombret, P. Fenaux, D. Grimwade, R. A. Larson, F. Lo-Coco, T. Naoe, D. Niederwieser, G. J. Ossenkoppele, M. A. Sanz, J. Sierra, M. S. Tallman, B. Löwenberg and C. D. Bloomfield: Diagnosis and management of acute myeloid leukemia in adults: recommendations from an international expert panel, on behalf of the European LeukemiaNet. Blood, 115(3), 453-474 (2010).
6. N. Howlader, A. M. Noone, M. Krapcho, N. Neyman, R. Aminou, W. Waldron, S. F. Altekruse, C. L. Kosary, J. Ruhl, Z. Tatalovich, H. Cho, A. Mariotto, M. P. Eisner, D. R. Lewis, H. S. Chen, E. J. Feuer, K. A. Cronin and B. K. Edwards: SEER Cancer Statistics Review, 1975-2008, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975-2008/, based on November 2010 SEER data submission, posted to the SEER web site, 2011 (2011).
7. A. Varki and T. Angata: Siglecs-the major subfamily of I-type lectins. Glycobiology, 16(1), 1R-27R (2006). (Pubitemid 43009801)
8. P. R. Crocker, J. C. Paulson and A. Varki: Siglecs and their roles in the immune system. Nat Rev Immunol, 7(4), 255-266 (2007). (Pubitemid 46480955)
9. H. Cao and P. R. Crocker: Evolution of CD33-related siglecs: regulating host immune functions and escaping pathogen exploitation? Immunology, 132(1), 18-26 (2011).
10. P. R. Crocker, S. J. McMillan and H. E. Richards: CD33-related siglecs as potential modulators of inflammatory responses. Ann N Y Acad Sci, 1253, 102- 111 (2012).
11. S. C. Peiper, R. A. Ashmun and A. T. Look: Molecular cloning, expression, and chromosomal localization of a human gene encoding the CD33 myeloid differentiation antigen. Blood, 72(1), 314-321 (1988).
12. D. Simmons and B. Seed: Isolation of a cDNA encoding CD33, a differentiation antigen of myeloid progenitor cells. J Immunol, 141(8), 2797-2800 (1988). (Pubitemid 18263070)
13. S. D. Freeman, S. Kelm, E. K. Barber and P. R. Crocker: Characterization of CD33 as a new member of the sialoadhesin family of cellular interaction molecules. Blood, 85(8), 2005-2012 (1995).
14. G. M. Yousef, M. H. Ordon, G. Foussias and E. P. Diamandis: Genomic organization of the siglec gene locus on chromosome 19q13.4 and cloning of two new siglec pseudogenes. Gene, 286(2), 259-270 (2002). (Pubitemid 34273882)
15. S. P. Paul, L. S. Taylor, E. K. Stansbury and D. W. McVicar: Myeloid specific human CD33 is an inhibitory receptor with differential ITIM function in recruiting the phosphatases SHP-1 and SHP-2. Blood, 96(2), 483-490 (2000). (Pubitemid 30463366)
16. T. Hernández-Caselles, M. Martínez-Esparza, A. B. Pérez-Oliva, A. M. Quintanilla-Cecconi, A. García- Alonso, D. M. R. Alvarez-López and P. Garcia- Peñarrubia: A study of CD33 (SIGLEC-3) antigen expression and function on activated human T and NK cells: two isoforms of CD33 are generated by alternative splicing. J Leukoc Biol, 79(1), 46-58 (2006). (Pubitemid 43054249)
17. V. C. Taylor, C. D. Buckley, M. Douglas, A. J. Cody, D. L. Simmons and S. D. Freeman: The myeloid-specific sialic acid-binding receptor, CD33, associates with the protein-tyrosine phosphatases, SHP-1 and SHP-2. J Biol Chem, 274(17), 11505-11512 (1999).
18. T. Ulyanova, J. Blasioli, T. A. Woodford-Thomas and M. L. Thomas: The sialoadhesin CD33 is a myeloidspecific inhibitory receptor. Eur J Immunol, 29(11), 3440- 3449 (1999). (Pubitemid 29527791)
19. S. J. Orr, N. M. Morgan, J. Elliott, J. F. Burrows, C. J. Scott, D. W. McVicar and J. A. Johnston: CD33 responses are blocked by SOCS3 through accelerated proteasomalmediated turnover. Blood, 109(3), 1061-1068 (2007). (Pubitemid 46220652)
20. R. B. Walter, P. Häusermann, B. W. Raden, A. M. Teckchandani, D. M. Kamikura, I. D. Bernstein and J. A. Cooper: Phosphorylated ITIMs enable ubiquitylation of an inhibitory cell surface receptor. Traffic, 9(2), 267-279 (2008).
21. K. Grobe and L. D. Powell: Role of protein kinase C in the phosphorylation of CD33 (Siglec-3) and its effect on lectin activity. Blood, 99(9), 3188-3196 (2002). (Pubitemid 34525297)
22. L. Balaian and E. D. Ball: Direct effect of bispecific anti-CD33 x anti-CD64 antibody on proliferation and signaling in myeloid cells. Leuk Res, 25(12), 1115-1125 (2001). (Pubitemid 33000495)
23. R. B. Walter, B. W. Raden, R. Zeng, P. Häusermann, I. D. Bernstein and J. A. Cooper: ITIM-dependent endocytosis of CD33-related Siglecs: role of intracellular domain, tyrosine phosphorylation, and the tyrosine phosphatases, Shp1 and Shp2. J Leukoc Biol, 83(1), 200-211 (2008).
24. R. G. Andrews, B. Torok-Storb and I. D. Bernstein: Myeloid-associated differentiation antigens on stem cells and their progeny identified by monoclonal antibodies. Blood, 62(1), 124-132 (1983). (Pubitemid 13070601)
25. J. D. Griffin, D. Linch, K. Sabbath, P. Larcom and S. F. Schlossman: A monoclonal antibody reactive with normal and leukemic human myeloid progenitor cells. Leuk Res, 8(4), 521- 534 (1984). (Pubitemid 14051256)
26. R. G. Andrews, M. Takahashi, G. M. Segal, J. S. Powell, I. D. Bernstein and J. W. Singer: The L4F3 antigen is expressed by unipotent and multipotent colony-forming cells but not by their precursors. Blood, 68(5), 1030-1035 (1986). (Pubitemid 17186377)
27. R. G. Andrews, J. W. Singer and I. D. Bernstein: Precursors of colony-forming cells in humans can be distinguished from colony-forming cells by expression of the CD33 and CD34 antigens and light scatter properties. J Exp Med, 169(5), 1721-1731 (1989). (Pubitemid 19126828)
28. M. Tanimoto, D. A. Scheinberg, C. Cordon-Cardo, D. Huie, B. D. Clarkson and L. J. Old: Restricted expression of an early myeloid and monocytic cell surface antigen defined by monoclonal antibody M195. Leukemia, 3(5), 339-348 (1989). (Pubitemid 19127556)
29. R. Handgretinger, H. J. Schafer, F. Baur, D. Frank, C. Ottenlinger, H. J. Buhring and D. Niethammer: Expression of an early myelopoietic antigen (CD33) on a subset of human umbilical cord blood-derived natural killer cells. Immunol Lett, 37(2-3), 223-228 (1993). (Pubitemid 23303738)
30. Y. Nakamura, M. Noma, M. Kidokoro, N. Kobayashi, M. Takei, S. Kurashima, T. Mukaiyama and S. Kato: Expression of CD33 antigen on normal human activated T lymphocytes. Blood, 83(5), 1442-1443 (1994). (Pubitemid 24062870)
31. I. G. Schmidt-Wolf, B. Grimm, P. Lefterova, V. Johnston, C. Scheffold, D. Huhn and S. Serke: Propagation of large numbers of cells of a human mixed-lineage Tlymphoid/myeloid. Br J Haematol, 90(3), 512-517 (1995).
32. C. Márquez, C. Trigueros, J. M. Franco, A. R. Ramiro, Y. R. Carrasco, M. López-Botet and M. L. Toribio: Identification of a common developmental pathway for thymic natural killer cells and dendritic cells. Blood, 91(8), 2760-2771 (1998). (Pubitemid 28227526)
33. M. N. Dworzak, G. Fritsch, G. Froschl, D. Printz and H. Gadner: Four-color flow cytometric investigation of terminal deoxynucleotidyl transferase-positive lymphoid precursors in pediatric bone marrow: CD79a expression precedes CD19 in early B-cell ontogeny. Blood, 92(9), 3203-3209 (1998). (Pubitemid 28492327)
34. E. Eksioglu-Demiralp, A. Kibaroglu, H. Direskeneli, S. Yavuz, F. Karsli, S. Yurdakul, H. Yazici and T. Akoglu: Phenotypic characteristics of B cells in Behcet's disease: increased activity in B cell subsets. J Rheumatol, 26(4), 826-832 (1999). (Pubitemid 29195669)
35. V. F. La Russa, J. D. Griffin, S. W. Kessler, M. A. Cutting, R. D. Knight, W. A. Blattler, J. M. Lambert and D. G. Wright: Effects of anti-CD33 blocked ricin immunotoxin on the capacity of CD34+ human marrow cells to establish in vitro hematopoiesis in long-term marrow cultures. Exp Hematol, 20(4), 442-448 (1992).
36. I. D. Bernstein, R. G. Andrews, R. Berenson, W. Bensinger, J. W. Singer and C. D. Buckner: Isolation of human hematopoietic stem cells. In: New Strategies in Bone Marrow Transplantation. Ed R. E. Champlin&R. P. Gale. Wiley-Liss, New York (1991).
37. M. J. Robertson, R. J. Soiffer, A. S. Freedman, S. L. Rabinowe, K. C. Anderson, T. J. Ervin, C. Murray, K. Dear, J. D. Griffin, L. M. Nadler and et al.: Human bone marrow depleted of CD33-positive cells mediates delayed but durable reconstitution of hematopoiesis: clinical trial of MY9 monoclonal antibody-purged autografts for the treatment of acute myeloid leukemia. Blood, 79(9), 2229- 2236 (1992).
38. M. P. Bodger and D. N. Hart: Molecular cloning and functional analysis of the CD33 promoter. Br J Haematol, 102(4), 986-995 (1998). (Pubitemid 28410530)
39. F. Lajaunias, J. M. Dayer and C. Chizzolini: Constitutive repressor activity of CD33 on human monocytes requires sialic acid recognition and phosphoinositide 3-kinase-mediated intracellular signaling. Eur J Immunol, 35(1), 243-251 (2005). (Pubitemid 40123871)
40. E. C. M. Brinkman-Van der Linden and A. Varki: New aspects of siglec binding specificities, including the significance of fucosylation and of the sialyl-Tn epitope. Sialic acid-binding immunoglobulin superfamily lectins. J Biol Chem, 275(12), 8625-8632 (2000). (Pubitemid 30180212)
41. D. Sgroi, A. Nocks and I. Stamenkovic: A single Nlinkes glycosylation site is implicated in the regulation of ligand recognition by the I-type lectins CD22 and CD33. J Biol Chem, 271, 18803-18809 (1996). (Pubitemid 26322750)
42. M. S. K. Sutherland, T. S. Lewis, C. Yu, J. A. McEarchern, J. G. Drachman, E. L. Sievers, I. S. Grewal and C.-L. Law: SGN-33 modulates cytokine and chemokine production by activated monocytes and macrophages [abstract]. Blood, 108(11), 564a (2006).
43. Y. Gonzalez, M. T. Herrera, G. Soldevila, L. Garcia- Garcia, G. Fabian, E. M. Pérez-Armendariz, K. Bobadilla, S. Guzmán-Beltrán, E. Sada and M. Torres: High glucose concentrations induce TNF-alpha production through the down-regulation of CD33 in primary human monocytes. BMC Immunol, 13, 19 (2012).
44. P. Hollingworth, D. Harold, R. Sims, A. Gerrish, J. C. Lambert, M. M. Carrasquillo, R. Abraham, M. L. Hamshere, J. S. Pahwa, V. Moskvina, K. Dowzell, N. Jones, A. Stretton, C. Thomas, A. Richards, D. Ivanov, C. Widdowson, J. Chapman, S. Lovestone, J. Powell, P. Proitsi, M. K. Lupton, C. Brayne, D. C. Rubinsztein, M. Gill, B. Lawlor, A. Lynch, K. S. Brown, P. A. Passmore, D. Craig, B. McGuinness, S. Todd, C. Holmes, D. Mann, A. D. Smith, H. Beaumont, D. Warden, G. Wilcock, S. Love, P. G. Kehoe, N. M. Hooper, E. R. Vardy, J. Hardy, S. Mead, N. C. Fox, M. Rossor, J. Collinge, W. Maier, F. Jessen, E. Ruther, B. Schurmann, R. Heun, H. Kolsch, H. van den Bussche, I. Heuser, J. Kornhuber, J. Wiltfang, M. Dichgans, L. Frolich, H. Hampel, J. Gallacher, M. Hull, D. Rujescu, I. Giegling, A. M. Goate, J. S. Kauwe, C. Cruchaga, P. Nowotny, J. C. Morris, K. Mayo, K. Sleegers, K. Bettens, S. Engelborghs, P. P. De Deyn, C. Van Broeckhoven, G. Livingston, N. J. Bass, H. Gurling, A. McQuillin, R. Gwilliam, P. Deloukas, A. Al-Chalabi, C. E. Shaw, M. Tsolaki, A. B. Singleton, R. Guerreiro, T. W. Muhleisen, M. M. Nothen, S. Moebus, K. H. Jockel, N. Klopp, H. E. Wichmann, V. S. Pankratz, S. B. Sando, J. O. Aasly, M. Barcikowska, Z. K. Wszolek, D. W. Dickson, N. R. Graff-Radford, R. C. Petersen, C. M. van Duijn, M. M. Breteler, M. A. Ikram, A. L. DeStefano, A. L. Fitzpatrick, O. Lopez, L. J. Launer, S. Seshadri, C. Berr, D. Campion : Common variants at ABCA7, MS4A6A/MS4A4E, EPHA1, CD33 and CD2AP are associated with Alzheimer's disease. Nat Genet, 43(5), 429- 435 (2011).
45. A. C. Naj, G. Jun, G. W. Beecham, L. S. Wang, B. N. Vardarajan, J. Buros, P. J. Gallins, J. D. Buxbaum, G. P. Jarvik, P. K. Crane, E. B. Larson, T. D. Bird, B. F. Boeve, N. R. Graff-Radford, P. L. De Jager, D. Evans, J. A. Schneider, M. M. Carrasquillo, N. Ertekin-Taner, S. G. Younkin, C. Cruchaga, J. S. Kauwe, P. Nowotny, P. Kramer, J. Hardy, M. J. Huentelman, A. J. Myers, M. M. Barmada, F. Y. Demirci, C. T. Baldwin, R. C. Green, E. Rogaeva, P. St George-Hyslop, S. E. Arnold, R. Barber, T. Beach, E. H. Bigio, J. D. Bowen, A. Boxer, J. R. Burke, N. J. Cairns, C. S. Carlson, R. M. Carney, S. L. Carroll, H. C. Chui, D. G. Clark, J. Corneveaux, C. W. Cotman, J. L. Cummings, C. DeCarli, S. T. DeKosky, R. Diaz-Arrastia, M. Dick, D. W. Dickson, W. G. Ellis, K. M. Faber, K. B. Fallon, M. R. Farlow, S. Ferris, M. P. Frosch, D. R. Galasko, M. Ganguli, M. Gearing, D. H. Geschwind, B. Ghetti, J. R. Gilbert, S. Gilman, B. Giordani, J. D. Glass, J. H. Growdon, R. L. Hamilton, L. E. Harrell, E. Head, L. S. Honig, C. M. Hulette, B. T. Hyman, G. A. Jicha, L. W. Jin, N. Johnson, J. Karlawish, A. Karydas, J. A. Kaye, R. Kim, E. H. Koo, N. W. Kowall, J. J. Lah, A. I. Levey, A. P. Lieberman, O. L. Lopez, W. J. Mack, D. C. Marson, F. Martiniuk, D. C. Mash, E. Masliah, Common variants at MS4A4/MS4A6E, CD2AP, CD33 and EPHA1 are associated with late-onset alzheimer's disease. Nat Genet, 43(5), 436-441 (2011).
46. Y. L. Deng, L. H. Liu, Y. Wang, H. D. Tang, R. J. Ren, W. Xu, J. F. Ma, L. L. Wang, J. P. Zhuang, G. Wang and S. D. Chen: The prevalence of CD33 and MS4A6A variant in Chinese Han population with Alzheimer's disease. Hum Genet, 131(7), 1245-1249 (2012).
47. P. A. Dinndorf, R. G. Andrews, D. Benjamin, D. Ridgway, L. Wolff and I. D. Bernstein: Expression of normal myeloid-associated antigens by acute leukemia cells. Blood, 67(4), 1048-1053 (1986). (Pubitemid 16116418)
48. I. Jilani, E. Estey, Y. Huh, Y. Joe, T. Manshouri, M. Yared, F. Giles, H. Kantarjian, J. Cortes, D. Thomas, M. Keating, E. Freireich and M. Albitar: Differences in CD33 intensity between various myeloid neoplasms. Am J Clin Pathol, 118(4), 560-566 (2002). (Pubitemid 44698513)
49. A. W. Hauswirth, S. Florian, D. Printz, K. Sotlar, M. T. Krauth, G. Fritsch, G. H. Schernthaner, V. Wacheck, E. Selzer, W. R. Sperr and P. Valent: Expression of the target receptor CD33 in CD34+/CD38-/CD123+ AML stem cells. Eur J Clin Invest, 37(1), 73-82 (2007). (Pubitemid 44934775)
50. D. A. Scheinberg, D. Lovett, C. R. Divgi, M. C. Graham, E. Berman, K. Pentlow, N. Feirt, R. D. Finn, B. D. Clarkson and T. S. Gee: A phase I trial of monoclonal antibody M195 in acute myelogenous leukemia: specific bone marrow targeting and internalization of radionuclide. J Clin Oncol, 9(3), 478-490 (1991).
51. P. C. Caron, M. S. Co, M. K. Bull, N. M. Avdalovic, C. Queen and D. A. Scheinberg: Biological and immunological features of humanized M195 (anti-CD33) monoclonal antibodies. Cancer Res, 52(24), 6761-6767 (1992). (Pubitemid 23006275)
52. R. H. C. van der Jagt, C. C. Badger, F. R. Appelbaum, O. W. Press, D. C. Matthews, J. F. Eary, K. A. Krohn and I. D. Bernstein: Localization of radiolabeled antimyeloid antibodies in a human acute leukemia xenograft tumor model. Cancer Res, 52(1), 89-94 (1992).
53. R. Audran, B. Drenou, F. Wittke, A. Gaudin, T. Lesimple and L. Toujas: Internalization of human macrophage surface antigens induced by monoclonal antibodies. J Immunol Methods, 188(1), 147-154 (1995). (Pubitemid 26014806)
54. O. W. Press, D. Shan, J. Howell-Clark, J. Eary, F. R. Appelbaum, D. Matthews, D. J. King, A. M. Haines, P. Hamann, L. Hinman, D. Shochat and I. D. Bernstein: Comparative metabolism and retention of iodine-125, yttrium-90, and indium-111 radioimmunoconjugates by cancer cells. Cancer Res, 56(9), 2123-2129 (1996). (Pubitemid 26119913)
55. V. H. J. van der Velden, J. G. te Marvelde, P. G. Hoogeveen, I. D. Bernstein, A. B. Houtsmuller, A. S. Berger and J. J. M. van Dogen: Targeting of the CD33- calicheamicin immunoconjugate Mylotarg (CMA-676) in acute myeloid leukemia: in vivo and in vitro saturation and internalization by leukemic and normal myeloid cells. Blood, 97(10), 3197-3204 (2001).
56. R. B. Walter, B. W. Raden, D. M. Kamikura, J. A. Cooper and I. D. Bernstein: Influence of CD33 expression levels and ITIM-dependent internalization on gemtuzumab ozogamicin-induced cytotoxicity. Blood, 105(3), 1295-1302 (2005). (Pubitemid 40170906)
57. J. E. Dick: Stem cell concepts renew cancer research. Blood, 112(13), 4793-4807 (2008).
58. R. B. Walter, F. R. Appelbaum, E. H. Estey and I. D. Bernstein: Acute myeloid leukemia stem cells and CD33-targeted immunotherapy. Blood, 119(26), 6198-6208 (2012).
59. R. Majeti: Monoclonal antibody therapy directed against human acute myeloid leukemia stem cells. Oncogene, 30(9), 1009-1019 (2011).
60. S. W. Lane and D. G. Gilliland: Leukemia stem cells. Semin Cancer Biol, 20(2), 71-76 (2010).
61. M. C. Stubbs and S. A. Armstrong: Therapeutic implications of leukemia stem cell development. Clin Cancer Res, 13(12), 3439-3442 (2007). (Pubitemid 46955102)
62. E. Passegué, C. H. Jamieson, L. E. Ailles and I. L. Weissman: Normal and leukemic hematopoiesis: are leukemias a stem cell disorder or a reacquisition of stem cell characteristics? Proc Natl Acad Sci U S A, 100 Suppl 1, 11842-11849 (2003). (Pubitemid 37205893)
63. P. J. Fialkow, J. W. Singer, J. W. Adamson, K. Vaidya, L. W. Dow, J. Ochs and J. W. Moohr: Acute nonlymphocytic leukemia: heterogeneity of stem cell origin. Blood, 57(6), 1068-1073 (1981). (Pubitemid 11050810)
64. P. J. Fialkow, J. W. Singer, W. H. Raskind, J. W. Adamson, R. J. Jacobson, I. D. Bernstein, L. W. Dow, V. Najfeld and R. Veith: Clonal development, stem-cell differentiation, and clinical remissions in acute nonlymphocytic leukemia. N Engl J Med, 317(8), 468-473 (1987). (Pubitemid 17131352)
65. D. Grimwade and T. Enver: Acute promyelocytic leukemia: where does it stem from? Leukemia, 18(3), 375- 384 (2004). (Pubitemid 38425848)
66. I. D. Bernstein, J. W. Singer, R. G. Andrews, A. Keating, J. S. Powell, B. H. Bjornson, J. Cuttner, V. Najfeld, G. Reaman, W. Raskind and et al.: Treatment of acute myeloid leukemia cells in vitro with a monoclonal antibody recognizing a myeloid differentiation antigen allows normal progenitor cells to be expressed. J Clin Invest, 79(4), 1153-1159 (1987). (Pubitemid 17065497)
67. I. D. Bernstein, J. W. Singer, F. O. Smith, R. G. Andrews, D. A. Flowers, J. Petersens, L. Steinmann, V. Najfeld, D. Savage, S. Fruchtman and et al.: Differences in the frequency of normal and clonal precursors of colonyforming cells in chronic myelogenous leukemia and acute myelogenous leukemia. Blood, 79(7), 1811-1816 (1992).
68. C. Vitale, C. Romagnani, M. Falco, M. Ponte, M. Vitale, A. Moretta, A. Bacigalupo, L. Moretta and M. C. Mingari: Engagement of p75/AIRM1 or CD33 inhibits the proliferation of normal or leukemic myeloid cells. Proc Natl Acad Sci U S A, 96(26), 15091-15096 (1999). (Pubitemid 30019770)
69. C. Vitale, C. Romagnani, A. Puccetti, D. Olive, R. Costello, L. Chiossone, A. Pitto, A. Bacigalupo, L. Moretta and M. C. Mingari: Surface expression and function of p75/AIRM-1 or CD33 in acute myeloid leukemias: engagement of CD33 induces apoptosis of leukemic cells. Proc Natl Acad Sci U S A, 98(10), 5764-5769 (2001). (Pubitemid 32435716)
70. P. C. Caron, J. G. Jurcic, A. M. Scott, R. D. Finn, C. R. Divgi, M. C. Graham, I. M. Jureidini, G. Sgouros, D. Tyson and L. J. Old: A phase 1B trial of humanized monoclonal antibody M195 (anti-CD33) in myeloid leukemia: specific targeting without immunogenicity. Blood, 83(7), 1760-1768 (1994). (Pubitemid 24107898)
71. J. G. Jurcic, T. DeBlasio, L. Dumont, T. J. Yao and D. A. Scheinberg: Molecular remission induction with retinoic acid and anti-CD33 monoclonal antibody HuM195 in acute promyelocytic leukemia. Clin Cancer Res, 6(2), 372-380 (2000). (Pubitemid 30111453)
72. P. C. Caron, L. Dumont and D. A. Scheinberg: Supersaturating infusional humanized anti-CD33 monoclonal antibody HuM195 in myelogenous leukemia. Clin Cancer Res, 4(6), 1421-1428 (1998). (Pubitemid 28265224)
73. E. Feldman, M. Kalaycio, G. Weiner, S. Frankel, P. Schulman, L. Schwartzberg, J. Jurcic, E. Velez-Garcia, K. Seiter, D. Scheinberg, D. Levitt and N. Wedel: Treatment of relapsed or refractory acute myeloid leukemia with humanized anti-CD33 monoclonal antibody HuM195. Leukemia, 17(2), 314-318 (2003). (Pubitemid 36266906)
74. A. Raza, J. G. Jurcic, G. J. Roboz, M. Maris, J. J. Stephenson, B. L. Wood, E. J. Feldman, N. Galili, L. E. Grove, J. G. Drachman and E. L. Sievers: Complete remissions observed in acute myeloid leukemia following prolonged exposure to lintuzumab: a phase 1 trial. Leuk Lymphoma, 50(8), 1336-1344 (2009).
75. E. J. Feldman, J. Brandwein, R. Stone, M. Kalaycio, J. Moore, J. O'Connor, N. Wedel, G. J. Roboz, C. Miller, R. Chopra, J. C. Jurcic, R. Brown, W. C. Ehmann, P. Schulman, S. R. Frankel, D. De Angelo and D. Scheinberg: Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia. J Clin Oncol, 23(18), 4110-4116 (2005). (Pubitemid 46211316)
76. M. A. Sekeres, J. E. Lancet, B. L. Wood, L. E. Grove, L. Sandalic, E. L. Sievers and J. G. Jurcic: Randomized, phase IIb study of low-dose cytarabine and placebo in older adults with untreated acute myeloid leukemia. Haematologica, 98(1), 119-128 (2013).
77. F. R. Appelbaum, D. C. Matthews, J. F. Eary, C. C. Badger, M. Kellogg, O. W. Press, P. J. Martin, D. R. Fisher, W. B. Nelp, E. D. Thomas and I. D. Bernstein: The use of radiolabeled anti-CD33 antibody to augment marrow irradiation prior to marrow transplantation for acute myelogenous leukemia. Transplantation, 54(5), 829-833 (1992).
78. N. K. Damle and P. Frost: Antibody-targeted chemotherapy with immunoconjugates of calicheamicin. Curr Opin Pharmacol, 3(4), 386-390 (2003). (Pubitemid 36908942)
79. M. D. Lee, T. S. Dunne, M. M. Siegel, C. C. Chang, G. O. Morton and D. B. Borders: Calichemicins, a novel family of antitumor antibiotics. 1. Chemistry and partial structure of calichemicin .gamma.1I. J Am Chem Soc, 109(11), 3464-3466 (1987). (Pubitemid 17125219)
80. M. D. Lee, T. S. Dunne, C. C. Chang, G. A. Ellestad, M. M. Siegel, G. O. Morton, W. J. McGahren and D. B. Borders: Calichemicins, a novel family of antitumor antibiotics. 2. Chemistry and structure of calichemicin .gamma.1I. J Am Chem Soc, 109(11), 3466-3468 (1987). (Pubitemid 17125220)
81. W. M. Maiese, M. P. Lechevalier, H. A. Lechevalier, J. Korshalla, N. Kuck, A. Fantini, M. J. Wildey, J. Thomas and M. Greenstein: Calicheamicins, a novel family of antitumor antibiotics: taxonomy, fermentation and biological properties. J Antibiot (Tokyo), 42(4), 558-563 (1989). (Pubitemid 19119095)
82. N. Zein, A. M. Sinha, W. J. McGahren and G. A. Ellestad: Calicheamicin gamma 1I: an antitumor antibiotic that cleaves double-stranded DNA site specifically. Science, 240(4856), 1198-1201 (1988).
83. K. Elmroth, J. Nygren, S. Mårtensson, I. H. Ismail and O. Hammarsten: Cleavage of cellular DNA by calicheamicin gamma1. DNA Repair (Amst), 2(4), 363-374 (2003). (Pubitemid 36253607)
84. P. C. Dedon, A. A. Salzberg and J. Xu: Exclusive production of bistranded DNA damage by calicheamicin. Biochemistry, 32(14), 3617-3622 (1993). (Pubitemid 23126936)
85. D. Amico, A. M. Barbui, E. Erba, A. Rambaldi, M. Introna and J. Golay: Differential response of human acute myeloid leukemia cells to gemtuzumab ozogamicin in vitro: role of Chk1 and Chk2 phosphorylation and caspase 3. Blood, 101(11), 4589-4597 (2003). (Pubitemid 36857832)
86. S. Mårtensson, J. Nygren, N. Osheroff and O. Hammarsten: Activation of the DNA-dependent protein kinase by drug-induced and radiation-induced DNA strand breaks. Radiat Res, 160(3), 291-301 (2003). (Pubitemid 37052427)
87. K. Naito, A. Takeshita, K. Shigeno, S. Nakamura, S. Fujisawa, K. Shinjo, H. Yoshida, K. Ohnishi, M. Mori, S. Terakawa and R. Ohno: Calicheamicin- conjugated humanized anti-CD33 monoclonal antibody (gemtuzumab ozogamicin, CMA-676) shows cytocidal effect on CD33- positive leukemia cell lines, but is inactive on Pglycoprotein- expressing sublines. Leukemia, 14(8), 1436- 1443 (2000). (Pubitemid 30601355)
88. J. Yuan, R. Adamski and J. Chen: Focus on histone variant H2AX: to be or not to be. FEBS Lett, 584(17), 3717-3724 (2010).
89. N. Sullivan and L. Lyne: Sensitivity of fibroblasts derived from ataxia-telangiectasia patients to calicheamicin gamma 1I. Mutat Res, 245(3), 171-175 (1990). (Pubitemid 20368890)
90. A. van Duijn-Goedhart, M. Z. Zdzienicka, K. Sankaranarayanan and P. P. van Buul: Differential responses of Chinese hamster mutagen sensitive cell lines to low and high concentrations of calicheamicin and neocarzinostatin. Mutat Res, 471(1-2), 95-105 (2000).
91. B. Zhao, S. Konno, J. M. Wu and A. L. Oronsky: Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by calicheamicin gamma 1 in human HL-60 cells. Cancer Lett, 50(2), 141-147 (1990). (Pubitemid 20119461)
92. A. Prokop, W. Wrasidlo, H. Lode, R. Herold, F. Lang, G. Henze, B. Dorken, T. Wieder and P. T. Daniel: Induction of apoptosis by enediyne antibiotic calicheamicin thetaII proceeds through a caspase-mediated mitochondrial amplification loop in an entirely Bax-dependent manner. Oncogene, 22(57), 9107-9120 (2003). (Pubitemid 38067986)
93. P. Haag, K. Viktorsson, M. L. Lindberg, L. Kanter, R. Lewensohn and L. Stenke: Deficient activation of Bak and Bax confers resistance to gemtuzumab ozogamicin-induced apoptotic cell death in AML. Exp Hematol, 37(6), 755-766 (2009).
94. C. M. H. Watanabe, L. Supekova and P. G. Schultz: Transcriptional effects of the potent enediyne anti-cancer agent calicheamicin γ1 I. Chem Biol, 9(2), 245-251 (2002). (Pubitemid 34196662)
95. L. M. Hinman, P. R. Hamann, R. Wallace, A. T. Menendez, F. E. Durr and J. Upeslacis: Preparation and characterization of monoclonal antibody conjugates of the calicheamicins: a novel and potent family of antitumor antibiotics. Cancer Res, 53(14), 3336-3342 (1993). (Pubitemid 23223306)
96. A. B. Pérez-Oliva, M. Martínez-Esparza, J. J. Vicente- Fernández, R. Corral-San Miguel, P. García-Peñarrubia and T. Hernández-Caselles: Epitope mapping, expression and post-translational modifications of two isoforms of CD33 (CD33M and CD33m) on lymphoid and myeloid human cells. Glycobiology, 21(6), 757-770 (2011).
97. P. R. Hamann, L. M. Hinman, C. F. Beyer, D. Lindh, J. Upeslacis, D. A. Flowers and I. Bernstein: An anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Choice of linker. Bioconjug Chem, 13(1), 40-46 (2002). (Pubitemid 34119633)
98. P. R. Hamann, L. M. Hinman, C. F. Beyer, L. M. Greenberger, C. Lin, D. Lindh, A. T. Menendez, R. Wallace, F. E. Durr and J. Upeslacis: An anti-MUC1 antibody-calicheamicin conjugate for treatment of solid tumors. Choice of linker and overcoming drug resistance. Bioconjug Chem, 16(2), 346-353 (2005). (Pubitemid 40388210)
99. P. R. Hamann, L. M. Hinman, I. Hollander, C. F. Beyer, D. Lindh, R. Holcomb, W. Hallett, H. R. Tsou, J. Upeslacis, D. Shochat, A. Mountain, D. A. Flowers and I. Bernstein: Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia. Bioconjug Chem, 13(1), 47-58 (2002). (Pubitemid 34119634)
100. A. F. Labrijn, A. O. Buijsse, E. T. van den Bremer, A. Y. Verwilligen, W. K. Bleeker, S. J. Thorpe, J. Killestein, C. H. Polman, R. C. Aalberse, J. Schuurman, J. G. van de Winkel and P. W. Parren: Therapeutic IgG4 antibodies engage in Fab-arm exchange with endogenous human IgG4 in vivo. Nat Biotechnol, 27(8), 767-771 (2009).
101. P. F. Bross, J. Beitz, G. Chen, X. H. Chen, E. Duffy, L. Kieffer, S. Roy, R. Sridhara, A. Rahman, G. Williams and R. Pazdur: Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia. Clin Cancer Res, 7(6), 1490-1496 (2001). (Pubitemid 32708610)
102. R. B. Walter, S. E. Fairchild, D. A. Flowers, T. C. Hong and I. D. Bernstein: Priming with myeloid growth factors enhances CD33 expression, decreases Pglycoprotein activity, and improves efficacy of gemtuzumab ozogamicin against acute myeloid leukemia (AML) colony forming cells (CFC) [abstract]. Blood, 112, 912a-913a (2008).
103. I. Jedema, R. M. Barge, V. H. van der Velden, B. A. Nijmeijer, J. J. van Dongen, R. Willemze and J. H. Falkenburg: Internalization and cell cycle-dependent killing of leukemic cells by gemtuzumab ozogamicin: rationale for efficacy in CD33-negative malignancies with endocytic capacity. Leukemia, 18(2), 316-325 (2004). (Pubitemid 38240048)
104. M. S. McGrath, M. G. Rosenblum, M. R. Philips and D. A. Scheinberg: Immunotoxin resistance in multidrug resistant cells. Cancer Res, 63(1), 72-79 (2003). (Pubitemid 36070422)
105. T. Yamauchi, Y. Matsuda, T. Tasaki, E. Negoro, S. Ikegaya, K. Takagi, A. Yoshida, Y. Urasaki and T. Ueda: Induction of DNA strand breaks is critical to predict the cytotoxicity of gemtuzumab ozogamicin against leukemic cells. Cancer Sci, 103(9), 1722-1729 (2012).
106. D. B. Rosen, K. H. Harrington, J. A. Cordeiro, L. Y. Leung, S. Putta, N. Lacayo, G. S. Laszlo, C. J. Gudgeon, D. E. Hogge, R. E. Hawtin, A. Cesano and R. B. Walter: AKT signaling as a novel factor associated with in vitro resistance of human AML to gemtuzumab ozogamicin. PLoS One, 8(1), e53518 (2013).
107. B. F. Goemans, C. M. Zwaan, S. J. Vijverberg, A. H. Loonen, U. Creutzig, K. Hahlen, D. Reinhardt, B. E. Gibson, J. Cloos and G. J. Kaspers: Large interindividual differences in cellular sensitivity to calicheamicin may influence gemtuzumab ozogamicin response in acute myeloid leukemia. Leukemia, 22(12), 2284-2285 (2008).
108. H. Matsui, A. Takeshita, K. Naito, K. Shinjo, K. Shigeno, M. Maekawa, Y. Yamakawa, M. Tanimoto, M. Kobayashi, K. Ohnishi and R. Ohno: Reduced effect of gemtuzumab ozogamicin (CMA-676) on P-glycoprotein and/or CD34-positive leukemia cells and its restoration by multidrug resistance modifiers. Leukemia, 16(5), 813-819 (2002). (Pubitemid 34537552)
109. R. B. Walter, B. W. Raden, T. C. Hong, D. A. Flowers, I. D. Bernstein and M. L. Linenberger: Multidrug resistance protein attenuates gemtuzumab ozogamicininduced cytotoxicity in acute myeloid leukemia cells. Blood, 102(4), 1466-1473 (2003). (Pubitemid 36988058)
110. R. B. Walter, B. W. Raden, M. R. Cronk, I. D. Bernstein, F. R. Appelbaum and D. E. Banker: The peripheral benzodiazepine receptor ligand PK11195 overcomes different resistance mechanisms to sensitize AML cells to gemtuzumab ozogamicin. Blood, 103(11), 4276-4284 (2004). (Pubitemid 38685374)
111. R. B. Walter, B. W. Raden, J. Thompson, D. A. Flowers, H. P. Kiem, I. D. Bernstein and M. L. Linenberger: Breast cancer resistance protein (BCRP/ABCG2) does not confer resistance to gemtuzumab ozogamicin and calicheamicin-gamma1 in acute myeloid leukemia cells. Leukemia, 18(11), 1914-1917 (2004). (Pubitemid 39530028)
112. R. B. Walter, J. L. Pirga, M. R. Cronk, S. Mayer, F. R. Appelbaum and D. E. Banker: PK11195, a peripheral benzodiazepine receptor (pBR) ligand, broadly blocks drug efflux to chemosensitize leukemia and myeloma cells by a pBR-independent, direct transporter-modulating mechanism. Blood, 106(10), 3584-3593 (2005). (Pubitemid 41609197)
113. R. Tang, A. M. Faussat, J. Y. Perrot, Z. Marjanovic, S. Cohen, T. Storme, H. Morjani, O. Legrand and J. P. Marie: Zosuquidar restores drug sensitivity in P-glycoprotein expressing acute myeloid leukemia (AML). BMC Cancer, 8, 51 (2008).
114. M. Jawad, C. Seedhouse, U. Mony, M. Grundy, N. H. Russell and M. Pallis: Analysis of factors that affect in vitro chemosensitivity of leukaemic stem and progenitor cells to gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukaemia. Leukemia, 24(1), 74-80 (2010).
115. T. Matsumoto, S. Jimi, S. Hara, Y. Takamatsu, J. Suzumiya and K. Tamura: Importance of inducible multidrug resistance 1 expression in HL-60 cells resistant to gemtuzumab ozogamicin. Leuk Lymphoma, 53(7), 1399- 1405 (2012).
116. L. Balaian and E. D. Ball: Cytotoxic activity of gemtuzumab ozogamicin (Mylotarg) in acute myeloid leukemia correlates with the expression of protein kinase Syk. Leukemia, 20(12), 2093-2101 (2006). (Pubitemid 44782834)
117. B. ten Cate, D. F. Samplonius, T. Bijma, L. F. de Leij, W. Helfrich and E. Bremer: The histone deacetylase inhibitor valproic acid potently augments gemtuzumab ozogamicin-induced apoptosis in acute myeloid leukemic cells. Leukemia, 21(2), 248-252 (2007). (Pubitemid 46158116)
118. M. Kurimoto, H. Matsuoka, N. Hanaoka, S. Uneda, T. Murayama, T. Sonoki and H. Nakakuma: Pretreatment of leukemic cells with low-dose decitabine markedly enhances the cytotoxicity of gemtuzumab ozogamicin. Leukemia, 27(1), 233-235 (2013).
119. M. Jawad, N. Yu, C. Seedhouse, K. Tandon, N. H. Russell and M. Pallis: Targeting of CD34+CD38- cells using Gemtuzumab ozogamicin (Mylotarg) in combination with tipifarnib (Zarnestra) in acute Myeloid Leukaemia. BMC Cancer, 12, 431 (2012).
120. R. B. Walter, K. M. Boyle, F. R. Appelbaum, I. D. Bernstein and J. M. Pagel: Simultaneously targeting CD45 significantly increases cytotoxicity of the anti-CD33 immunoconjugate, gemtuzumab ozogamicin, against acute myeloid leukemia (AML) cells and improves survival of mice bearing human AML xenografts. Blood, 111(9), 4813- 4816 (2008).
121. M. Tanaka, Y. Kano, M. Akutsu, S. Tsunoda, T. Izumi, Y. Yazawa, S. Miyawaki, H. Mano and Y. Furukawa: The cytotoxic effects of gemtuzumab ozogamicin (mylotarg) in combination with conventional antileukemic agents by isobologram analysis in vitro. Anticancer Res, 29(11), 4589-4596 (2009).
122. K. L. Morris, J. A. Adams and J. A. Liu: Effect of gemtuzumab ozogamicin on acute myeloid leukemia blast cells in vitro, as a single agent and combined with other cytotoxic cells. Br J Haematol, 135(4), 509-512 (2006). (Pubitemid 44583415)
123. M. K. Sutherland, C. Yu, T. S. Lewis, J. B. Miyamoto, C. A. Morris-Tilden, M. Jonas, J. Sutherland, A. Nesterova, H. P. Gerber, E. L. Sievers, I. S. Grewal and C. L. Law: Anti-leukemic activity of lintuzumab (SGN-33) in preclinical models of acute myeloid leukemia. MAbs, 1(5), 481-490 (2009).
124. J. A. Dowell, J. Korth-Bradley, H. Liu, S. P. King and M. S. Berger: Pharmacokinetics of gemtuzumab ozogamicin, an antibody-targeted chemotherapy agent for the treatment of patients with acute myeloid leukemia in first relapse. J Clin Pharmacol, 41(11), 1206-1214 (2001). (Pubitemid 32983219)
125. J. M. Korth-Bradley, J. A. Dowell, S. P. King, H. Liu and M. S. Berger: Impact of age and gender on the pharmacokinetics of gemtuzumab ozogamicin. Pharmacotherapy, 21(10), 1175-1180 (2001). (Pubitemid 32939090)
126. M. Buckwalter, J. A. Dowell, J. Korth-Bradley, B. Gorovits and P. R. Mayer: Pharmacokinetics of gemtuzumab ozogamicin as a single-agent treatment of pediatric patients with refractory or relapsed acute myeloid leukemia. J Clin Pharmacol, 44(8), 873-880 (2004). (Pubitemid 38971569)
127. Y. Kobayashi, K. Tobinai, A. Takeshita, K. Naito, O. Asai, N. Dobashi, S. Furusawa, K. Saito, K. Mitani, Y. Morishima, M. Ogura, F. Yoshiba, T. Hotta, M. Bessho, S. Matsuda, J. Takeuchi, S. Miyawaki, T. Naoe, N. Usui and R. Ohno: Phase I/II study of humanized anti-CD33 antibody conjugated with calicheamicin, gemtuzumab ozogamicin, in relapsed or refractory acute myeloid leukemia: final results of Japanese multicenter cooperative study. Int J Hematol, 89(4), 460-469 (2009).
128. E. L. Sievers, F. R. Appelbaum, R. T. Spielberger, S. J. Forman, D. Flowers, F. O. Smith, K. Shannon-Dorcy, M. S. Berger and I. D. Bernstein: Selective ablation of acute myeloid leukemia using antibody-targeted chemotherapy: a phase I study of an anti-CD33 calicheamicin immunoconjugate. Blood, 93(11), 3678-3684 (1999). (Pubitemid 29249814)
129. E. L. Sievers, R. A. Larson, E. A. Stadtmauer, E. Estey, B. Lowenberg, H. Dombret, C. Karanes, M. Theobald, J. M. Bennett, M. L. Sherman, M. S. Berger, C. B. Eten, M. R. Loken, J. J. van Dongen, I. D. Bernstein and F. R. Appelbaum: Efficacy and safety of gemtuzumab ozogamicin in patients with CD33-positive acute myeloid leukemia in first relapse. J Clin Oncol, 19(13), 3244-3254 (2001). (Pubitemid 32591442)
130. R. A. Larson, E. L. Sievers, E. A. Stadtmauer, B. Löwenberg, E. H. Estey, H. Dombret, M. Theobald, D. Voliotis, J. M. Bennett, M. Richie, L. H. Leopold, M. S. Berger, M. L. Sherman, M. R. Loken, J. J. M. van Dongen, I. D. Bernstein, F. R. Appelbaum and . Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer, 104(7), 1442-1452 (2005). (Pubitemid 41356159)
131. F. Giles, E. Estey and S. O'Brien: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer, 98(10), 2095-2104 (2003). (Pubitemid 37392412)
132. C. Fenton and C. M. Perry: Gemtuzumab ozogamicin: a review of its use in acute myeloid leukaemia. Drugs, 65(16), 2405-2427 (2005). (Pubitemid 41573610)
133. A. M. Tsimberidou, F. J. Giles, E. Estey, S. O'Brien, M. J. Keating and H. M. Kantarjian: The role of gemtuzumab ozogamicin in acute leukaemia therapy. Br J Haematol, 132(4), 398-409 (2006). (Pubitemid 43381615)
134. S. A. Abutalib and M. S. Tallman: Monoclonal antibodies for the treatment of acute myeloid leukemia. Curr Pharm Biotechnol, 7(5), 343-369 (2006). (Pubitemid 44524417)
135. L. Pagano, L. Fianchi, M. Caira, S. Rutella and G. Leone: The role of Gemtuzumab Ozogamicin in the treatment of acute myeloid leukemia patients. Oncogene, 26(25), 3679-3690 (2007). (Pubitemid 46842699)
136. R. Stasi, M. L. Evangelista, F. Buccisano, A. Venditti and S. Amadori: Gemtuzumab ozogamicin in the treatment of acute myeloid leukemia. Cancer Treat Rev, 34(1), 49-60 (2008). (Pubitemid 351168609)
137. M. Breccia and F. Lo-Coco: Gemtuzumab ozogamicin for the treatment of acute promyelocytic leukemia: mechanisms of action and resistance, safety and efficacy. Expert Opin Biol Ther, 11(2), 225-234 (2011).
138. F. Lo-Coco, G. Cimino, M. Breccia, N. I. Noguera, D. Diverio, E. Finolezzi, E. M. Pogliani, E. Di Bona, C. Micalizzi, M. Kropp, A. Venditti, A. Tafuri and F. Mandelli: Gemtuzumab ozogamicin (Mylotarg) as a single agent for molecularly relapsed acute promyelocytic leukemia. Blood, 104(7), 1995-1999 (2004). (Pubitemid 39297848)
139. M. C. Petti, M. B. Pinazzi, D. Diverio, A. Romano, M. T. Petrucci, S. De Santis, G. Meloni, A. Tafuri, F. Mandelli and F. Lo Coco: Prolonged molecular remission in advanced acute promyelocytic leukaemia after treatment with gemtuzumab ozogamicin (Mylotarg CMA-676). Br J Haematol, 115(1), 63-65 (2001). (Pubitemid 32995094)
140. M. Breccia, G. Cimino, D. Diverio, F. Gentilini, F. Mandelli and F. Lo Coco: Sustained molecular remission after low dose gemtuzumab-ozogamicin in elderly patients with advanced acute promyelocytic leukemia. Haematologica, 92(9), 1273-1274 (2007). (Pubitemid 350144194)
141. E. H. Estey, F. J. Giles, M. Beran, S. O'Brien, S. A. Pierce, S. H. Faderl, J. E. Cortes and H. M. Kantarjian: Experience with gemtuzumab ozogamycin ("mylotarg") and all-trans retinoic acid in untreated acute promyelocytic leukemia. Blood, 99(11), 4222-4224 (2002). (Pubitemid 35332070)
142. F. Ravandi, E. Estey, D. Jones, S. Faderl, S. O'Brien, J. Fiorentino, S. Pierce, D. Blamble, Z. Estrov, W. Wierda, A. Ferrajoli, S. Verstovsek, G. Garcia-Manero, J. Cortes and H. Kantarjian: Effective treatment of acute promyelocytic leukemia with all-trans-retinoic acid, arsenic trioxide, and gemtuzumab ozogamicin. J Clin Oncol, 27(4), 504-510 (2009).
143. A. L. Taksin, O. Legrand, E. Raffoux, T. de Revel, X. Thomas, N. Contentin, R. Bouabdallah, C. Pautas, P. Turlure, O. Reman, C. Gardin, B. Varet, S. de Botton, F. Pousset, H. Farhat, S. Chevret, H. Dombret and S. Castaigne: High efficacy and safety profile of fractionated doses of Mylotarg as induction therapy in patients with relapsed acute myeloblastic leukemia: a prospective study of the alfa group. Leukemia, 21(1), 66-71 (2007). (Pubitemid 44921836)
144. H. Farhat, O. Reman, E. Raffoux, C. Berthon, C. Pautas, L. Kammoun, S. Chantepie, C. Gardin, P. Rousselot, S. Chevret, H. Dombret and S. Castaigne: Fractionated doses of gemtuzumab ozogamicin with escalated doses of daunorubicin and cytarabine as first acute myeloid leukemia salvage in patients aged 50-70-year old: A phase 1/2 study of the acute leukemia French association. Am J Hematol, 87(1), 62-65 (2012).
145. S. Castaigne, C. Pautas, C. Terré, E. Raffoux, D. Bordessoule, J. N. Bastie, O. Legrand, X. Thomas, P. Turlure, O. Reman, T. de Revel, L. Gastaud, N. de Gunzburg, N. Contentin, E. Henry, J. P. Marolleau, A. Aljijakli, P. Rousselot, P. Fenaux, C. Preudhomme, S. Chevret and H. Dombret: Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, openlabel, phase 3 study. Lancet, 379(9825), 1508-1516 (2012).
146. A. K. Burnett, R. K. Hills, D. Milligan, L. Kjeldsen, J. Kell, N. H. Russell, J. A. L. Yin, A. Hunter, A. H. Goldstone and K. Wheatley: Identification of patients with acute myeloblastic leukaemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial J Clin Oncol, 29(4), 369-377 (2011).
147. J. Delaunay, C. Recher, A. Pigneux, F. Witz, N. Vey, O. Blanchet, P. Lefebvre, I. Luquet, I. Guillerme, C. Volteau, E. Gyan, B. Lioure, E. Jourdan, D. Bouscary, R. Guieze, E. Randriamalala, M. E. Ojeda Uribe, F. Dreyfus, C. Lacombe, M. C. Béné, J. Y. Cahn, J. L. Harousseau and N. Ifrah: Addition of gemtuzumab ozogamycin to chemotherapy improves event-free survival but not overall survival of AML patients with intermediate cytogenetics not eligible for allogeneic transplantation. Results of the GOELAMS AML 2006 IR study [abstract #79]. Blood, 118(21), 37-38 (2011).
148. A. K. Burnett, N. H. Russell, R. K. Hills, J. Kell, S. Freeman, L. Kjeldsen, A. E. Hunter, J. Yin, C. F. Craddock, I. H. Dufva, K. Wheatley and D. Milligan: Addition of gemtuzumab ozogamicin to induction chemotherapy improves survival in older patients with acute myeloid leukemia. J Clin Oncol, 30(32), 3924-3931 (2012).
149. S. Petersdorf, K. Kopecky, R. K. Stuart, R. A. Larson, T. J. Nevill, L. Stenke, M. L. Slovak, M. S. Tallman, C. L. Willman, H. Erba and F. R. Appelbaum: Preliminary results of Southwest Oncology Group Study S0106: an international intergroup phase 3 randomized trial comparing the addition of gemtuzumab ozogamicin to standard induction therapy versus standard induction therapy followed by a second randomization to postconsolidation gemtuzumab ozogamicin versus no additional therapy for previously untreated acute myeloid leukemia [abstract #790]. Blood, 114(22), 326-327 (2009).
150. SWOG (2010): http://www.swogstat.org/ROS/ROSBooks/Spring2010/Leukemia. pdf. Accessed on: December 26, 2012.
151. H. F. Fernandez, Z. Sun, M. R. Litzow, S. M. Luger, E. M. Paietta, J. Racevskis, G. Dewald, R. P. Ketterling, J. M. Rowe, H. M. Lazarus and M. S. Tallman: Autologous transplantation gives encouraging results for young adults with favorable-risk acute myeloid leukemia, but is not improved with gemtuzumab ozogamicin. Blood, 117(20), 5306-5313 (2011).
152. B. Löwenberg, J. Beck, C. Graux, W. van Putten, H. C. Schouten, L. F. Verdonck, A. Ferrant, P. Sonneveld, M. Jongen-Lavrencic, M. von Lilienfeld-Toal, B. J. Biemond, E. Vellenga, D. Breems, H. de Muijnck, R. Schaafsma, G. Verhoef, H. Döhner, A. Gratwohl, T. Pabst, G. J. Ossenkoppele and J. Maertens: Gemtuzumab ozogamicin as postremission treatment in AML at 60 years of age or more: results of a multicenter phase 3 study. Blood, 115(13), 2586-2591 (2010).
153. A. K. Burnett, R. K. Hills, A. E. Hunter, D. Milligan, W. J. Kell, K. Wheatley, J. Yin, M. F. McMullin, H. Dignum, D. Bowen and N. H. Russell: The addition of gemtuzumab ozogamicin to low-dose Ara-C improves remission rate but does not significantly prolong survival in older patients with acute myeloid leukaemia: results from the LRF AML14 and NCRI AML16 pick-a-winner comparison. Leukemia, 27(1), 75-81 (2013).
154. Pfizer Inc (2010): http://media.pfizer.com/files/products/mylotarg-hcp- letter.pdf. Accessed on: December 26, 2012.
155. A. D. Ricart: Antibody-drug conjugates of calicheamicin derivative: gemtuzumab ozogamicin and inotuzumab ozogamicin. Clin Cancer Res, 17(20), 6417- 6427 (2011).
156. M. L. Linenberger, T. Hong, D. Flowers, E. L. Sievers, T. A. Gooley, J. M. Bennett, M. S. Berger, L. H. Leopold, F. R. Appelbaum and I. D. Bernstein: Multidrugresistance phenotype and clinical responses to gemtuzumab ozogamicin. Blood, 98(4), 988-994 (2001).
157. D. Steinbach and O. Legrand: ABC transporters and drug resistance in leukemia: was P-gp nothing but the first head of the Hydra? Leukemia, 21(6), 1172-1176 (2007). (Pubitemid 46831804)
158. M. Dean, T. Fojo and S. Bates: Tumour stem cells and drug resistance. Nat Rev Cancer, 5(4), 275-284 (2005). (Pubitemid 40488633)
159. R. B. Walter, T. A. Gooley, V. H. van der Velden, M. R. Loken, J. J. van Dongen, D. A. Flowers, I. D. Bernstein and F. R. Appelbaum: CD33 expression and Pglycoprotein- mediated drug efflux inversely correlate and predict clinical outcome in patients with acute myeloid leukemia treated with gemtuzumab ozogamicin monotherapy. Blood, 109(10), 4168-4170 (2007). (Pubitemid 46743379)
160. J. A. Pollard, T. A. Alonzo, M. Loken, R. B. Gerbing, P. A. Ho, I. D. Bernstein, S. C. Raimondi, B. Hirsch, J. Franklin, R. B. Walter, A. Gamis and S. Meshinchi: Correlation of CD33 expression level with disease characteristics and response to gemtuzumab ozogamicin containing chemotherapy in childhood AML. Blood, 119(16), 3705-3711 (2012).
161. P. A. Dinndorf, J. D. Buckley, M. E. Nesbit, B. C. Lampkin, S. Piomelli, S. A. Feig, J. H. Kersey, G. D. Hammond and I. D. Bernstein: Expression of myeloid differentiation antigens in acute nonlymphocytic leukemia: increased concentration of CD33 antigen predicts poor outcome-a report from the Childrens Cancer Study Group. Med Pediatr Oncol, 20(3), 192- 200 (1992).
162. J. Lamba, L. J. Mortland, A. Mitra, R. B. Walter, J. A. Pollard, T. A. Alonzo, R. B. Gerbing, B. A. Hirsch, S. C. Raimondi, J. Franklin and S. Meshinchi: Clinical significance of CD33 non-synonymous single nucleotide polymorphisms (SNPs) in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin-containing chemotherapy [abstract]. Blood, 118(21), 1489 (2011).
163. L. Mortland, T. A. Alonzo, R. B. Walter, R. B. Gerbing, A. K. Mitra, J. A. Pollard, M. R. Loken, B. Hirsch, S. Raimondi, J. Franklin, S. Pounds, X. Cao, J. E. Rubnitz, R. C. Ribeiro, A. Gamis, S. Meshinchi and J. K. Lamba: Clinical significance of CD33 nonsynonymous single nucleotide polymorphisms (SNPs) in pediatric patients with acute myeloid leukemia treated with gemtuzumab ozogamicin-containing chemotherapy. Clin Cancer Res (2013), in press.
164. I. Middeldorf, O. Galm, R. Osieka, E. Jost, J. G. Herman and S. Wilop: Sequence of administration and methylation of SOCS3 may govern response to gemtuzumab ozogamicin in combination with conventional chemotherapy in patients with refractory or relapsed acute myelogenous leukemia (AML). Am J Hematol, 85(7), 477-481 (2010).
165. F. J. Giles, J. E. Cortes, T. A. Halliburton, S. J. Mallard, E. H. Estey, T. A. Waddelow and J. T. Lim: Intravenous corticosteroids to reduce gemtuzumabozogamicin infusion reactions. Ann Pharmacother, 37(9), 1182-1185 (2003). (Pubitemid 37040205)
166. M. B. Maniecki, H. Hasle, L. Friis-Hansen, B. Lausen, O. J. Nielsen, K. Bendix, S. K. Moestrup and H. J. Moller: Impaired CD163-mediated hemoglobin-scavenging and severe toxic symptoms in patients treated with gemtuzumab ozogamicin. Blood, 112(4), 1510-1514 (2008).
167. F. J. Giles, H. M. Kantarjian, S. M. Kornblau, D. A. Thomas, G. Garcia-Manero, T. A. Waddelow, C. L. David, A. T. Phan, D. E. Colburn, A. Rashid and E. H. Estey: Mylotarg (gemtuzumab ozogamicin) therapy is associated with hepatic venoocclusive disease in patients who have not received stem cell transplantation. Cancer, 92(2), 406- 413 (2001). (Pubitemid 32664448)
168. G. B. McDonald: Management of hepatic sinusoidal obstruction syndrome following treatment with gemtuzumab ozogamicin (Mylotarg). Clin Lymphoma, 2 Suppl 1, S35-39 (2002). (Pubitemid 34436373)
169. M. Wadleigh, P. G. Richardson, D. Zahrieh, S. J. Lee, C. Cutler, V. Ho, E. P. Alyea, J. H. Antin, R. M. Stone, R. J. Soiffer and D. J. DeAngelo: Prior gemtuzumab ozogamicin exposure significantly increases the risk of veno-occlusive disease in patients who undergo myeloablative allogeneic stem cell transplantation. Blood, 102(5), 1578-1582 (2003). (Pubitemid 37022544)
170. J. M. McKoy, C. Angelotta, C. L. Bennett, M. S. Tallman, M. Wadleigh, A. M. Evens, T. M. Kuzel, S. M. Trifilio, D. W. Raisch, J. Kell, D. J. DeAngelo and F. J. Giles: Gemtuzumab ozogamicin-associated sinusoidal obstructive syndrome (SOS): an overview from the research on adverse drug events and reports (RADAR) project. Leuk Res, 31(5), 599-604 (2007). (Pubitemid 46578145)
171. B. Versluys, R. Bhattacharaya, C. Steward, J. Cornish, A. Oakhill and N. Goulden: Prophylaxis with defibrotide prevents veno-occlusive disease in stem cell transplantation after gemtuzumab ozogamicin exposure. Blood, 103(5), 1968 (2004). (Pubitemid 38269002)
172. D. Lannoy, B. Decaudin, A. Grozieux de Laguerenne, F. Barrier, J. M. Pignon, M. Wetterwald and P. Odou: Gemtuzumab ozogamicin-induced sinusoidal obstructive syndrome treated with defibrotide: a case report. J Clin Pharm Ther, 31(4), 389-392 (2006). (Pubitemid 44060204)
173. P. Rajvanshi, H. M. Shulman, E. L. Sievers and G. B. McDonald: Hepatic sinusoidal obstruction after gemtuzumab ozogamicin (Mylotarg) therapy. Blood, 99(7), 2310-2314 (2002). (Pubitemid 34525414)
174. M. B. Maniecki, H. Hasle, K. Bendix and H. J. Moller: Is hepatotoxicity in patients treated with gemtuzumabozogamicin due to specific targeting of hepatocytes? Leuk Res, 35(6), e84- 86 (2011).
175. E. Estey: Treatment of AML: resurrection for gemtuzumab ozogamicin? Lancet, 379(9825), 1468-1469 (2012).
176. J. M. Foran: Gemtuzumab: time to bring back on the market? Clin Adv Hematol Oncol, 10(5), 326-327 (2012).
177. D. S. Neuberg: Reprise: gemtuzumab ozogamicin for older patients with acute myeloid leukemia. J Clin Oncol, 30(32), 3905-3906 (2012).
178. F. Ravandi, E. H. Estey, F. R. Appelbaum, F. Lo- Coco, C. A. Schiffer, R. A. Larson, A. K. Burnett and H. M. Kantarjian: Gemtuzumab ozogamicin: time to resurrect? J Clin Oncol, 30(32), 3921-3923 (2012).
179. E. Jager, V. H. van der Velden, J. G. te Marvelde, R. B. Walter, Z. Agur and V. Vainstein: Targeted drug delivery by gemtuzumab ozogamicin: mechanism-based mathematical model for treatment strategy improvement and therapy individualization. PLoS One, 6(9), e24265 (2011).
180. S. Lapusan, M. B. Vidriales, X. Thomas, S. de Botton, A. Vekhoff, R. Tang, C. Dumontet, R. Morariu-Zamfir, J. M. Lambert, M. L. Ozoux, P. Poncelet, J. F. San Miguel, O. Legrand, D. J. Deangelo, F. J. Giles and J. P. Marie: Phase I studies of AVE9633, an anti-CD33 antibodymaytansinoid conjugate, in adult patients with relapsed/refractory acute myeloid leukemia. Invest New Drugs, 30(3), 1121-1131 (2012).
181. B. ten Cate, E. Bremer, M. de Bruyn, T. Bijma, D. Samplonius, M. Schwemmlein, G. Huls, G. Fey and W. Helfrich: A novel AML-selective TRAIL fusion protein that is superior to gemtuzumab ozogamicin in terms of in vitro selectivity, activity and stability. Leukemia, 23(8), 1389-1397 (2009).
182. M. S. K. Sutherland, R. B. Walter, S. C. Jeffrey, P. J. Burke, C. Yu, K. H. Harrington, I. Stone, M. C. Ryan, D. Sussman, W. Zeng, D. R. Benjamin, I. Bernstein, P. D. Senter, J. G. Drachman and J. A. McEarchern: SGNCD33A: a novel CD33-directed antibody-drug conjugate, utilizing pyrrolobenzodiazepine dimers, demonstrates preclinical antitumor activity against multi-drug resistant human AML [abstract #3589]. 54th Annual Meeting of the American Society of Hematology, December 8-11, 2012, Atlanta, GA (2012).
183. M. Aigner, J. Feulner, S. Schaffer, R. Kischel, P. Kufer, K. Schneider, A. Henn, B. Rattel, M. Friedrich, P. A. Baeuerle, A. Mackensen and S. W. Krause: T lymphocytes can be effectively recruited for ex vivo and in vivo lysis of AML blasts by a novel CD33/CD3-bispecific BiTE((R)) antibody construct. Leukemia (2012); in press.
184. K.-H. Heider, R. Konopitzky, E. Ostermann, H. Lamche, Z. Küpcü, C. Kössl, P. J. Adam, G. R. Adolf and E. Borges: A novel Fc-engineered antibody to CD33 with enhanced ADCC activity for treatment of AML [abstract #1363]. 54th Annual Meeting of the American Society of Hematology, December 8-11, 2012, Atlanta, GA (2012).
185. R. B. Walter, F. R. Appelbaum, M. S. Tallman, N. S. Weiss, R. A. Larson and E. H. Estey: Shortcomings in the clinical evaluation of new drugs: acute myeloid leukemia as paradigm. Blood, 116(14), 2420-2428 (2010).